Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.
Bomben R, Zucchetto A, Laureana R, Chiarenza A, Olivieri J, Tissino E, Rossi FM, Vit F, Bittolo T, Papotti R, Pozzo F, Gaglio A, Degan M, Polesel J, Marasca R, Visentin A, Moia R, Innocenti I, Vitale C, Murru R, Varettoni M, Tafuri A, Zaja F, Postorino M, Martino EA, Condoluci A, Rossi D, Cuneo A, Di Raimondo F, Sportoletti P, Del Giudice I, Foà R, Mauro FR, Coscia M, Laurenti L, Gaidano G, Trentin L, Principe MID, Gentile M, Gattei V. Bomben R, et al. Among authors: postorino m. Hemasphere. 2024 Jul 15;8(7):e128. doi: 10.1002/hem3.128. eCollection 2024 Jul. Hemasphere. 2024. PMID: 39011128 Free PMC article. No abstract available.
CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias.
Buccisano F, Rossi FM, Venditti A, Del Poeta G, Cox MC, Abbruzzese E, Rupolo M, Berretta M, Degan M, Russo S, Tamburini A, Maurillo L, Del Principe MI, Postorino M, Amadori S, Gattei V. Buccisano F, et al. Among authors: postorino m. Br J Haematol. 2004 Apr;125(2):203-12. doi: 10.1111/j.1365-2141.2004.04883.x. Br J Haematol. 2004. PMID: 15059143 Free article.
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S. Del Poeta G, et al. Among authors: postorino m. Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Drugs Today (Barc). 2016. PMID: 27252989 Review.
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A. Tissino E, et al. Among authors: postorino m. J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4. J Exp Med. 2018. PMID: 29301866 Free PMC article.
Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia.
Del Poeta G, Biagi A, Laurenti L, Chiarenza A, Pozzo F, Innocenti I, Postorino M, Rossi FM, Del Principe MI, Bomben R, de Fabritiis P, Bruno A, Cantonetti M, Di Raimondo F, Zucchetto A, Gattei V. Del Poeta G, et al. Among authors: postorino m. Haematologica. 2021 Sep 1;106(9):2345-2353. doi: 10.3324/haematol.2020.251488. Haematologica. 2021. PMID: 32732360 Free PMC article.
COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
Del Poeta G, Bomben R, Polesel J, Rossi FM, Pozzo F, Zaina E, Cattarossi I, Varaschin P, Nanni P, Boschian Boschin R, Postorino M, Laureana R, Pasqualone G, Steffan A, Gentile M, Zucchetto A, Gattei V. Del Poeta G, et al. Among authors: postorino m. Hematol Oncol. 2021 Dec;39(5):712-714. doi: 10.1002/hon.2916. Epub 2021 Aug 30. Hematol Oncol. 2021. PMID: 34462939 Free PMC article. No abstract available.
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Tedeschi A, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, Reda G, Laurenti L, Varettoni M, Murru R, Baratè C, Sportoletti P, Greco A, Borella C, Rossi V, Deodato M, Biagi A, Zamprogna G, Pelle AC, Lapietra G, Vitale C, Morelli F, Cassin R, Fresa A, Cavalloni C, Postorino M, Ielo C, Cairoli R, Di Raimondo F, Montillo M, Del Poeta G. Tedeschi A, et al. Among authors: postorino m. Blood Adv. 2021 Dec 28;5(24):5490-5500. doi: 10.1182/bloodadvances.2021004824. Blood Adv. 2021. PMID: 34525181 Free PMC article.
COVID-19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients.
Del Poeta G, Laureana R, Bomben R, Rossi FM, Pozzo F, Zaina E, Cattarossi I, Varaschin P, Nanni P, Boschian Boschin R, Nunzi A, Postorino M, Pasqualone G, Brisotto G, Steffan A, Muraro E, Zucchetto A, Del Principe MI, Gattei V. Del Poeta G, et al. Among authors: postorino m. Hematol Oncol. 2023 Aug;41(3):559-562. doi: 10.1002/hon.3121. Epub 2023 Jan 9. Hematol Oncol. 2023. PMID: 36585917 Free PMC article. No abstract available.
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
Bomben R, Rossi FM, Vit F, Bittolo T, Zucchetto A, Papotti R, Tissino E, Pozzo F, Degan M, Polesel J, Bulian P, Marasca R, Reda G, Laurenti L, Olivieri J, Chiarenza A, Laureana R, Postorino M, Del Principe MI, Cuneo A, Gentile M, Morabito F, Fronza G, Tafuri A, Zaja F, Foà R, Di Raimondo F, Del Poeta G, Gattei V. Bomben R, et al. Among authors: postorino m. Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18. Leukemia. 2023. PMID: 36807650 Free PMC article. No abstract available.
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
Pozzo F, Forestieri G, Vit F, Ianna G, Tissino E, Bittolo T, Papotti R, Gaglio A, Terzi di Bergamo L, Steffan A, Polesel J, Bulian P, Laureana R, Tafuri A, Chiarenza A, Di Raimondo F, Olivieri J, Zaja F, Laurenti L, Del Principe MI, Postorino M, Del Poeta G, Bomben R, Zucchetto A, Rossi D, Gattei V. Pozzo F, et al. Among authors: postorino m. Leukemia. 2024 Aug;38(8):1712-1721. doi: 10.1038/s41375-024-02301-y. Epub 2024 Jun 24. Leukemia. 2024. PMID: 38914716 Free PMC article.
174 results